Loading...
•
Dec 31, 2020
Cencora Q1 2021 Earnings Report
Reported revenue increase of 9.7 percent year-over-year to $52.5 billion, GAAP diluted EPS of $1.81, and adjusted diluted EPS of $2.18.
Key Takeaways
AmerisourceBergen reported a strong first quarter in fiscal year 2021, with revenue increasing by 9.7% year-over-year to $52.5 billion. GAAP diluted EPS was $1.81, and adjusted diluted EPS increased by 24% to $2.18. The company raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $8.40 to $8.60.
Revenue increased by 9.7% year-over-year to $52.5 billion.
GAAP diluted EPS was $1.81, compared to $0.90 in the prior year quarter.
Adjusted diluted EPS increased by 24% to $2.18.
Adjusted diluted EPS guidance was raised to $8.40 to $8.60 for fiscal year 2021.
Cencora
Cencora
Forward Guidance
AmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company’s continued strong performance and solid execution. This updated financial guidance does not include any contribution from the proposed Alliance Healthcare acquisition or any incremental growth from the expanded U.S. partnership announced in January 2021.
Positive Outlook
- Revenue growth in the high-single digit percent range, up from the mid-single digit percent range.
- Adjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.
- Adjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent range.
- Adjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range.
- Pharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from the mid-single digit percent range.